How big is Amedisys, Inc.?

As of Jun 18, Amedisys, Inc. has a market capitalization of $3.69 billion, with net sales of $2.37 billion and a net profit of $85.38 million over the last four quarters.

Market Cap: As of Jun 18, Amedisys, Inc. has a market capitalization of 3,694.47 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Amedisys, Inc. reported net sales of 2,371.69 million and a net profit of 85.38 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,134.54 million and total assets of 2,138.71 million.

What does Amedisys, Inc. do?

Amedisys, Inc. is a healthcare services company that provides home health, hospice, and personal care services, with a recent net sales of $595 million and a market cap of approximately $3.69 billion. Key financial metrics include a P/E ratio of 20.00 and a return on equity of 15.00%.

Overview: <BR>Amedisys, Inc. is a healthcare services company operating in the Pharmaceuticals & Biotechnology industry, providing home health, hospice, and personal care services.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 595 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 62 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,694.47 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.09 <BR>Return on Equity: 15.00% <BR>Price to Book: 3.08<BR><BR>Contact Details: <BR>Address: 3854 American Way Ste A, BATON ROUGE LA: 70816-4013 <BR>Tel: ['1 225 2922031', '1 855 2592046'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.amedisys.com/

Who are in the management team of Amedisys, Inc.?

As of March 2022, Amedisys, Inc.'s management team includes Paul Kusserow (Chairman, President, CEO), Richard Lechleiter (Lead Independent Director), and several Independent Directors: Ivanetta Samuels, Vickie Capps, Molly Coye, and Julie Klapstein. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Amedisys, Inc. includes the following individuals:<BR><BR>- Mr. Paul Kusserow serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Mr. Richard Lechleiter is the Lead Independent Director.<BR>- Ms. Ivanetta Samuels is a Director.<BR>- Ms. Vickie Capps is an Independent Director.<BR>- Dr. Molly Coye is also an Independent Director.<BR>- Ms. Julie Klapstein serves as an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Should I buy, sell or hold Amedisys, Inc.?

Is Amedisys, Inc. overvalued or undervalued?

As of August 14, 2025, Amedisys, Inc. is considered very expensive with a P/E ratio of 20, higher than its peers and industry averages, and has underperformed the S&P 500 significantly, indicating it may be overvalued despite a low PEG ratio of 0.30.

As of 14 August 2025, the valuation grade for Amedisys, Inc. has moved from expensive to very expensive, indicating a significant shift in its valuation outlook. The company appears overvalued, with a P/E ratio of 20, compared to a peer average P/E of approximately 17.89, and an EV to EBITDA ratio of 15.03, which is higher than the industry average. Additionally, the PEG ratio stands at a notably low 0.30, suggesting that the stock may not be justified at its current price given its growth prospects.<BR><BR>In comparison to its peers, Encompass Health Corp. has a P/E of 20.94 and The Ensign Group, Inc. shows a much higher P/E of 32.46, both indicating that Amedisys is trading at a premium relative to these companies. Furthermore, Amedisys's recent stock performance has lagged behind the S&P 500, with a 1-year return of 2.58% compared to the index's 17.14%, and a staggering 5-year return of -56.15% versus the S&P's 96.61%. This underperformance reinforces the view that Amedisys is overvalued in the current market environment.

Is Amedisys, Inc. technically bullish or bearish?

As of July 29, 2025, Amedisys, Inc. shows a bullish technical trend with strong indicators like MACD and Bollinger Bands, despite long-term underperformance compared to the S&P 500.

As of 29 July 2025, the technical trend for Amedisys, Inc. has changed from mildly bullish to bullish. The weekly MACD and Bollinger Bands are bullish, and daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly timeframes, while the OBV shows a mildly bullish trend. However, the RSI indicates no signal on both weekly and monthly charts, and Dow Theory shows no trend in either timeframe. <BR><BR>In terms of multi-period returns, Amedisys has outperformed the S&P 500 over the past week and month, but it has significantly underperformed over the 1-year, 3-year, and 5-year periods. Overall, the current technical stance is bullish, supported by strong indicators, but the long-term performance remains a concern.